王岩  (副研究员)

Huang W, Yang T, Ma S, Wang J, Gong H, Wang H, Sun J, Wang N, Zhang L, Wang Yan*.  Comparative evaluation of multimodal point-of-care tests to differentiate gram-negative from gram-positive infections in critically ill adults: a diagnostic accuracy study. Infection. 2026 Jan 14. doi: 10.1007/s15010-025-02720-8.

Wei D, Ma S, Huang W, Yang T, Chen K, Sun B, Li X, Zhang L, Wang Yan*.  Whether an optimal strategy exists for VTE prevention in critically ill patients: Insights from guidelines and randomized controlled trials. Eur J Intern Med. 2025 Dec:142:106426.（中科院医学2区）

Wang H, Ma S, Huang W, Chen K, Xie J, Wang N, Li Y, Yang Q, Yang X, Wang Yan*.  Impact of Proton Pump Inhibitors on Osimertinib-Induced Cardiotoxicity in NSCLC Patients. Cardiovasc Toxicol. 2025;25(7):1084-1093.

Chen K, Wang C, Wei Y, Ma S, Huang W, Dong Y, Wang Yan*.  Machine learning and population pharmacokinetics: a hybrid approach for optimizing vancomycin therapy in sepsis patients. Microbiol Spectr. 2025 Mar 31:e0049925.（中科院生物学2区）

Wang H, Chen K, Ma S, Huang W, Xie J, Wang N, Li Y, Yang Q, Yang X, Wang Yan*.  PPIs effect in EGFR-TKI-associated interstitial lung diseases in patients with non-small cell lung cancer. BMC Cancer. 2025;25(1):263.

Liu Y, Dai M, Zhang K, Zhang L, Lin B, Chen K, Wang H, Gu Z, Yu Y, Wang Yan*. Risk of Clostridioides difficile infection following different antibiotics: insights from multi-source medical data. Int J Antimicrob Agents. 2024 Jul 31;64(4):107288.（中科院药学1区）

Zhang Li, Li Ping, Liu Chenwei, Zheng Qiwen, Wang Yan*. Low early anti-factor Xa target achievement rate of low molecular weight heparin for treating venous thromboembolism in intensive care unit patients. J Clin Pharmacol. 2023 Jun;63(6):664-671.

Xing Yuanming, Qiu Yulan, Yang Luting, Yuan Zuyi, Wang Yan *. Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model. Int J Cardiol. 2023 Jan 15;371:420-426.（中科院医学2区）

Xie J, Yang Q, Han X, Dong Y, Zhang T, Li Y, Ji M, Liu C, Cai Y, Wang Y*. Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: A Step toward Dose Optimization Using Monte Carlo Simulation. Antimicrob Agents Chemother. 2022 Jun 21;66(6): e0009922; （中科院药学1区）

Wang Y*, Mieke L Van Driel, Treasure M McGuire, Samantha A Hollingworth. Trends in systemic antifungal use in Australia, 2005-2016: a time-series analysis. Jpn J Infect Dis. 2022 May 24;75(3):254-261;

Han R, Teng M, Zhang Y, Zhang T, Wang T, Chen J, Li S, Yang B, Shi Y, Dong Y*, Wang Y*. Choosing Optimal Antibiotics for the Treatment of Patients Infected With Enterobacteriaceae: A Network Meta-analysis and Cost-Effectiveness Analysis. Front Pharmacol. 2021 Jun 17; 12:656790; （中科院药学2区）

Wang Y, Zhang Y, TM McGuire, SA Hollingworth, ML Van Driel, Cao L, Wang X, Dong Y*. ICU patients' antibiotic exposure and triazole-resistance in invasive candidiasis: parallel analysis of aggregated and individual data. Front Pharmacol. 2021 Mar 22; 12:586893;（中科院药学2区）

Wang Y^#*, Zhong H^#, Han X, Wang N, Cai Y, Wang H, Yu J, Zhang X, Zhang K*. Impact of antibiotic prescription on the resistance of Klebsiella pneumoniae at a tertiary hospital in China, 2012-2019. Am J Infect Control. 2021, 49(1): 65-69;

Wang Y*, Treasure M McGuire, Samantha A Hollingworth, Dong Y, Mieke L Van Driel. Antifungal agents for invasive candidiasis in non-neutropenic critically ill adults: what do the guidelines recommend? Int J Infect Dis. 2019, 89: 137-145;（中科院医学2区）

Wang Y, Xing Y, Chen L, Meng T, Li Y, Xie J, Chen L, Dong Y*, Dong W*. Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis. Int J Hematology, 2018, 107(2): 235-243；

Wang Y, Xie J, Xing Y, Chen L, Li Y, Meng T, Dong W, Wang X, Dong Y*. Choosing optimal antifungal agents to prevent fungal infections in nonneutropenic critically ill patients: trial sequential analysis, network meta-analysis, and pharmacoeconomic analysis. Antimicrob Agents Chemother, 2017, 61(12): e00620-17；（中科院药学1区）

Wang Y, Yang Q, Chen L, Liu L, Hao R, Zhang T, Wang X, Lei J, Xie J, Dong Y*. Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study. Eur J Clin Microbiol Infect Dis, 2017, 36(11): 2117-2126；

Wang Y, Wang T, Xie J, Yang Q, Zheng X, Dong W, Xing J, Wang X, Dong Y*. Risk factors for voriconazole-associated hepatotoxicity in patients in the intensive care unit. Pharmacotherapy, 2016, 36(7): 757-765;（中科院医学2区）

Wang Y, Zou Y, Xie J, Wang T, Zheng X, He H, Dong W, Xing J, Dong Y*. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol, 2015, 71(1): 107-115；

Zhong H^#, Wang Y^#, Zhang Z, Liu Y, Le K, Cui M, Yu Y*, Gu Z*, Gao Y, Lin H*. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacol Res. 2020, 157: 104872；（中科院医学1区，ESI高被引）

Zhang Y^#, Wang Y^#, Van Driel ML, McGuire TM, Zhang T, Dong Y, Liu Y, Liu L, Hao R, Cao L, Xing J, Dong Y*. Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia. Antimicrob Resist Infect Control, 2019, 8:72.（中科院医学2区）

Zhang Li^#, Wang Yan^#, Ping Li, Wang Haitao, Cai Yan, Wang Na, Liu Chenwei, Fang Yu*. Impact of clinical pharmacist services on physicians' guideline compliance and prognosis of patients for venous thromboembolism prophylaxis in ICU. Int J Clin Pharmacol Ther. 2023 Jan;61:24-32.

王岩, 董亚琳, 张抗怀. 抗侵袭性念珠菌药物管理指标与治疗方案一致性对重症患者预后的影响.临床药物治疗杂志, 2021, 19(12): 45-48.

王海涛, 张抗怀, 谢姣, 王娜, 杨乾婷, 蔡艳, 李友佳, 张莉, 王岩*. 临床药师对重症监护室抗菌药物相关药物相互作用的研究及药学服务. 中国药师, 2023, 26 (10): 125-131.